Status:

UNKNOWN

Self-guided Acceptance and Commitment Therapy-based Digital Smartphone Application for Management of Fibromyalgia

Lead Sponsor:

Fundació Sant Joan de Déu

Collaborating Sponsors:

Swing Therapeutics, Inc.

Conditions:

Fibromyalgia

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

Introduction: Fibromyalgia (FM) is a prevalent syndrome that lacks curative treatment, imposing high healthcare and societal costs. The SMART-FM-Spain study investigates the effectiveness, physiologic...

Detailed Description

Main goals of the SMART-FM-SP study The main objectives of this RCT are: To analyze the effectiveness of adding Acceptance and Commitment Therapy via app (STANZA) compared to an active control arm (Fi...

Eligibility Criteria

Inclusion

  • Fibromyalgia diagnosis according to the 2016 ACR criteria
  • Fibromyalgia Impact Questionnaire Revised (FIQR) total score within the range of 35-80 at baseline.
  • Willing to maintain their current pain treatment throughout the study.
  • Having a smartphone (iOS 12 or higher or Android OS 8 or higher).
  • Proficient understanding of Spanish.

Exclusion

  • Presence of cognitive impairment according to clinical records.
  • Diagnosis of severe medical or mental disorders such as cancer, psychotic disorder, and drug abuse according to medical records.
  • Patients at risk of suicide.
  • Being pregnant or planning a pregnancy during the study period, or currently breastfeeding.
  • Participation in other clinical trials during the study or within the previous 90 days.
  • Unable to use a smartphone.
  • Exclusion criteria for biomarkers substudy (50% of patients in each study arm):
  • Comorbid rheumatologic disorders such as lupus.
  • History of fever (\> 38ºC), or infection within the last 2 weeks.
  • Recent vaccination within the last 4 weeks.
  • Needle phobia.
  • Consumption of more than 8 units of caffeine per day.
  • Smoking more than 5 cigarettes per day.
  • Having hair length less than 3 cm.

Key Trial Info

Start Date :

January 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

360 Patients enrolled

Trial Details

Trial ID

NCT05962437

Start Date

January 1 2024

End Date

December 31 2025

Last Update

July 27 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Parc Sanitari Sant Joan de Déu (PSSJD)

Sant Boi de Llobregat, Barcelona, Spain, 08830

2

Hospital Vall d'Hebrón

Barcelona, Spain, 08035